Share on StockTwits

XOMA Corp (NASDAQ:XOMA) CEO John Varian sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $4.54, for a total value of $45,400.00. Following the transaction, the chief executive officer now directly owns 285,613 shares of the company’s stock, valued at approximately $1,296,683. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

A number of research firms have recently commented on XOMA. Analysts at Wedbush raised their price target on shares of XOMA Corp to $14.00 in a research note on Monday, May 12th. They now have an “outperform” rating on the stock. Analysts at MLV & Co
upgraded shares of XOMA Corp from a “hold” rating to a “buy” rating in a research note on Tuesday, April 29th. They now have a $7.00 price target on the stock. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $9.11.

Shares of XOMA Corp (NASDAQ:XOMA) traded up 0.21% on Wednesday, hitting $4.88. 1,881,399 shares of the company’s stock traded hands. XOMA Corp has a 1-year low of $3.31 and a 1-year high of $9.57. The stock has a 50-day moving average of $4.1 and a 200-day moving average of $5.90. The company’s market cap is $521.7 million.

XOMA Corp (NASDAQ:XOMA) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.06. The company had revenue of $3.41 million for the quarter, compared to the consensus estimate of $7.40 million. During the same quarter in the previous year, the company posted ($0.30) earnings per share. The company’s revenue for the quarter was down 63.9% on a year-over-year basis. Analysts expect that XOMA Corp will post $-0.65 EPS for the current fiscal year.

XOMA Corporation (NASDAQ:XOMA) is engaged in the discovery and development of antibody-based therapeutics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.